Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuromodulators in Esophageal Disorders of Gut-brain Interaction
NCT06778824Recruiting
- Sponsor
- Hualien Tzu Chi Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of imipramine and sertraline in esophageal disorders of gut-brain interaction and gastroesophageal reflux disease (GERD) (3 arms), sponsored by Hualien Tzu Chi Hospital. Primary endpoints: Gastroesophageal Reflux Disease Questionnaire at 12 weeks, PROMIS Gastroesophageal Reflux Disease Questionnaire at 12 weeks and 13 more. Started Apr 2024; status: recruiting.
02
Drugs
imipraminesertraline
03
Conditions
esophageal disorders of gut-brain interactiongastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06778824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778824.